Inbakicept (C09-1140-279)

Inbakicept (ALT-803) is an IL-15 superagonist complex, consisting of IL-15 mutant and IL-15Rα-Fc fusion. Inbakicept magnifies anti-CD20 mAb-mediated NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation, IFNγ production in cellsIn VitroInbakicept (0.01-1 nM; 20 hr) enhances human NK cell cytotoxicity and increases cytotoxic effector molecule expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: Daudi, Raji, CD19 + FL cells Concentration: 0.01 nM, 0.1 nM, and 1 nM Incubation Time: 20 hours Result: Increased the human NK cell cytotoxicity on Daudi, Raji, CD19 + FL cells.In VivoInbakicept (0.2 mg/kg; i.v.; twice weekly, for 2 weeks) enhances rituximab-directed protection from a lethal Daudi lymphoma challenge in mouse model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID mice with Daudi models Dosage: 0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg Administration: Intravenous injection; twice weekly, for 2 weeks Result: Enhanced rituximab-directed control of Raji lymphoma challenge.IC50& Target:IL-15Rα.